Department of Chemistry
Jan. 21, 2016—Vanderbilt investigators have developed a way to detect malaria that is faster and more sensitive than current clinical methods — a development that has the potential to make malaria detection significantly less expensive and more stable.
Oct. 22, 2015—Walter Chazin, Ph.D., director of the Vanderbilt Center for Structural Biology, is a recipient of a 2016 Fellow of the Biophysical Society award.
Oct. 2, 2015—New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs.
Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
Aug. 26, 2015—Vanderbilt investigators have developed a framework for studying cellular responses that could be used to identify the agents driving a range of biological processes in health and disease.
Aug. 7, 2015—Vanderbilt researchers have discovered how certain molecules with antibiotic properties are synthesized, findings that could lead to new drugs that overcome the increased antibiotic resistance in bacteria.
Jun. 22, 2015—Richard N. Armstrong, Ph.D., professor of Biochemistry and Chemistry, prominent biochemist, journal editor and mentor, died on June 18 after a brief illness. He was 66.
Jun. 17, 2015—A new imaging probe developed by Vanderbilt investigators enhances tumor visibility and has broad applications in diagnosing and monitoring patients with cancer.
Jun. 12, 2015—Inhibitors of the enzyme phospholipase D1 suppress the replication of HIV-1, Vanderbilt investigators have discovered.
Mar. 10, 2015—Vanderbilt and the Waters Centers of Innovation Program are sponsoring a free symposium titled "Integrated 'Omics in Translational Medicine" on March 23. It is open to all scientists interested in the subject.
Sep. 12, 2014—Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.
Jun. 20, 2014—Vanderbilt's John McLean has received Agilent Technology's Thought Leader Award in recognition of his contributions to ion mobility mass spectrometry.